Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 11/20 | 1.00 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.37 |
| ▸ | EEF2K | O00418 | 1/20 | 0.37 |
| ▸ | PLK1 | P53350 | 1/20 | 0.37 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | BUB1 | O43683 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22408453 | 1.00 | PIK3C3 (1.00) | PIK3C3GSK3AGSK3BKITCYP3A4 | |
| SCHEMBL20774921 | 0.89 | PIK3C3 (0.80) | PIK3C3CYP3A4AAK1 | |
| SCHEMBL26612404 | 0.88 | PIK3C3 (0.79) | PIK3C3GSK3AGSK3BKITNR3C2 | |
| SCHEMBL20764978 | 0.87 | PIK3C3 (0.78) | PIK3C3CYP3A4AAK1 | |
| SCHEMBL20765267 | 0.85 | PIK3C3 (0.74) | PIK3C3GSK3B | |
| SCHEMBL20764777 | 0.83 | PIK3C3 (1.00) | PIK3C3GSK3AGSK3B | |
| SCHEMBL29035847 | 0.81 | PIK3C3 (0.71) | PIK3C3KITCYP3A4 | |
| SCHEMBL29701003 | 0.79 | PIK3C3 (0.77) | PIK3C3 | |
| SCHEMBL20765374 | 0.79 | PIK3C3 (0.77) | PIK3C3 | |
| SCHEMBL20765560 | 0.77 | PIK3C3 (1.00) | PIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4384180-A1 | COMBINATION THERAPY OF VPS34 INHIBITORS AND STING AGONIST FOR USE IN THE TREATMENT OF CANCER | Deciphera Pharmaceuticals, LLC (US) | 2024-06-19 | — | — | EP | claimed |
| CN-118201619-A | Combination therapy of VPS34 inhibitors with STING agonists for the treatment of cancer | 德西费拉制药有限责任公司 | 2024-06-14 | — | — | CN | claimed |
| CN-117083064-A | Pyridinylpyridone derivatives as VPS34 inhibitors for the treatment of viral infections | 德西费拉制药有限责任公司 | 2023-11-17 | — | — | CN | claimed |
| EP-4251152-A1 | PYRIDYLPYRIDONE DERIVATIVES AS VSP34 INHIBITORS FOR USE IN THE TREATMENT OF A VIRAL INFECTION | Deciphera Pharmaceuticals, LLC (US) | 2023-10-04 | — | — | EP | claimed |
| CN-111094244-B | Pyridinylpyridinone compounds | 思普瑞特生物科学公司 | 2023-07-11 | — | — | CN | claimed |
| WO-2023019259-A1 | COMBINATION THERAPY OF VPS34 INHIBITORS AND STING AGONIST FOR USE IN THE TREATMENT OF CANCER | DECIPHERA PHARMACEUTICALS, LLC (US) | 2023-02-16 | — | — | WO | claimed |
| US-20220184050-A1 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC | 2022-06-16 | — | — | US | claimed |
| WO-2022115545-A1 | PYRIDYLPYRIDONE DERIVATIVES AS VSP34 INHIBITORS FOR USE IN THE TREATMENT OF A VIRAL INFECTION | DECIPHERA PHARMACEUTICALS, LLC (US) | 2022-06-02 | — | — | WO | claimed |
| EP-4384180-A1 | COMBINATION THERAPY OF VPS34 INHIBITORS AND STING AGONIST FOR USE IN THE TREATMENT OF CANCER | Deciphera Pharmaceuticals, LLC (US) | 2024-06-19 | — | — | EP | disclosed |
| CN-118201619-A | Combination therapy of VPS34 inhibitors with STING agonists for the treatment of cancer | 德西费拉制药有限责任公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-117083064-A | Pyridinylpyridone derivatives as VPS34 inhibitors for the treatment of viral infections | 德西费拉制药有限责任公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-116903526-A | Pyridinylpyridinone compounds | 思普瑞特生物科学公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-116891431-A | Pyridinylpyridinone compounds | 思普瑞特生物科学公司 | 2023-10-17 | — | — | CN | disclosed |
| EP-4251152-A1 | PYRIDYLPYRIDONE DERIVATIVES AS VSP34 INHIBITORS FOR USE IN THE TREATMENT OF A VIRAL INFECTION | Deciphera Pharmaceuticals, LLC (US) | 2023-10-04 | — | — | EP | disclosed |
| CN-111094244-B | Pyridinylpyridinone compounds | 思普瑞特生物科学公司 | 2023-07-11 | — | — | CN | disclosed |
| WO-2023019259-A1 | COMBINATION THERAPY OF VPS34 INHIBITORS AND STING AGONIST FOR USE IN THE TREATMENT OF CANCER | DECIPHERA PHARMACEUTICALS, LLC (US) | 2023-02-16 | — | — | WO | disclosed |
| US-20220184050-A1 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC | 2022-06-16 | — | — | US | disclosed |
| WO-2022115545-A1 | PYRIDYLPYRIDONE DERIVATIVES AS VSP34 INHIBITORS FOR USE IN THE TREATMENT OF A VIRAL INFECTION | DECIPHERA PHARMACEUTICALS, LLC (US) | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220184050-A1 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS | SARS1, VPS26B, VPS4B | PIK3C3 1967/4885GSK3A 4067/4885GSK3B 3686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.